FDA Sends 25 Warning Letters Over False Claims on Compounded GLP-1 Drugs
Updated
Updated · Reuters · Jun 16
FDA Sends 25 Warning Letters Over False Claims on Compounded GLP-1 Drugs
3 articles · Updated · Reuters · Jun 16
Summary
Twenty-five warning letters were posted Tuesday after the FDA accused telehealth firms including Medica Weight Loss, Ready Med and Clover Meds of misleading marketing for compounded weight-loss and diabetes drugs.
The agency said some companies falsely claimed compounded semaglutide or tirzepatide came from FDA-approved pharmacies, used clinically studied ingredients, or matched approved GLP-1 medicines.
Semaglutide underpins Novo Nordisk's Ozempic and Wegovy, while tirzepatide is used in Eli Lilly's Mounjaro and Zepbound; compounded versions are not FDA-approved and have not been proven safe, effective or consistent in quality.
The letters extend the FDA's broader crackdown on compounded GLP-1 products after it previously warned telehealth firms and in April proposed removing Lilly and Novo's obesity drugs from a key compounding list.